Cingulate Inc. (CING) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cingulate Inc. (CING) closed at USD 4.57 on 2026-10-14, a change of +25.5 % over the past year, with a market capitalization of USD 63.84M.

Cingulate Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cingulate Inc. key figures

Previous close

USD 4.57 (2026-10-14)

1-year change

+25.5 %

Market cap

USD 63.84M

Enterprise value

USD 41.73M

P/E ratio (trailing)

-1.34

P/E ratio (forward)

-4.99

EPS (trailing)

-3.28

EPS (forward)

-0.88

PEG ratio

n/a

Price to book

2.60

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.46

Employees

14

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cingulate Inc.

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cingulate Inc. and compare it with other stocks.